Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-25 | New | $1,389,676 | $1,389,676 | Equity Only | 06b | SEC link |
| 2024-04-09 | New | $1,262,000 | $1,262,000 | Equity Only | 06b | SEC link |
| 2024-02-02 | New | $2,565,225 | $2,565,225 | Equity Only | 06b | SEC link |
| 2023-08-14 | New | $6,706,941 | $6,706,941 | Debt Only | 06b | SEC link |
| 2022-09-14 | New | $11,234,000 | $11,234,000 | Debt Only | 06b | SEC link |
| Name | Role |
|---|---|
| Iain Baird | Director |
| Mark Bamforth | Director |
| James Barnes | Executive |
| David Lawrence | Director |
| Christopher Lea | Director, Executive |
| James Roger Mc Ilroy | Director, Executive |
| Felix Andy Awili Olale | Director |
| Elmar Josef Schnee | Director |
| Melissa Strange | Executive |
| Douglas Campbell Thomson | Director |